Drug updated on 11/15/2023
|Capsule (oral: 40 mg, 80 mg)
| Ongoing and
- For the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC).
- For the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.
- For the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).
- For the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.
Product Monograph / Prescribing Information
|Retevmo (selpercatinib) Prescribing Information.
|Lilly USA, LLC, Indianapolis, IN
Systematic Reviews / Meta-Analyses
|Clinical, pharmacoeconomic, and stakeholder input combined report.
|Efficacy and Safety of RET-Specific Kinase Inhibitors in RET-Altered Cancers:
|Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer.
|Clinical and pharmacoeconomic combined report.
Clinical Practice Guidelines
|Therapy for stage iv non–small-cell lung cancer with driver alterations: ASCO living guideline.
|Journal of Clinical Oncology
|NCCN guidelines insights: non–small cell lung cancer, version 2.2021.
|Journal of the National Comprehensive Cancer Network